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Abstract
Background: Gastric carcinoma is one of the most frequent cancers worldwide. Patients with gastric cancer at an advanced
disease stage have a poor prognosis, due to the limited efficacy of available therapies. Therefore, the development of new
therapies, like immunotherapy for the treatment of gastric cancer is of utmost importance. Since the usability of existing
preclinical models for the evaluation of immunotherapies for gastric adenocarcinomas is limited, the goal of the present study
was to establish murine in vivo models which allow the stepwise improvement of immunotherapies for gastric cancer.
Methods: Since no murine gastric adenocarcinoma cell lines are available we established four cell lines (424GC, mGC3, mGC5,
mGC8) from spontaneously developing tumors of CEA424/SV40 T antigen (CEA424/Tag) mice and three cell lines derived from
double-transgenic offsprings of CEA424/Tag mice mated with human carcinoembryonic antigen (CEA)-transgenic (CEA424/Tag-
CEA) mice (mGC2CEA, mGC4CEA, mGC11CEA). CEA424/Tag is a transgenic C57BL/6 mouse strain harboring the Tag under the
control of a -424/-8 bp CEA gene promoter which leads to the development of invasive adenocarcinoma in the glandular
stomach. Tumor cell lines established from CEA424/Tag-CEA mice express the well defined tumor antigen CEA under the
control of its natural regulatory elements.
Results: The epithelial origin of the tumor cells was proven by morphological criteria including the presence of mucin within
the cells and the expression of the cell adhesion molecules EpCAM and CEACAM1. All cell lines consistently express the
transgenes CEA and/or Tag and MHC class I molecules leading to their susceptibility to lysis by Tag-specific CTL in vitro. Despite
the presentation of CTL-epitopes derived from the transgene products the tumor cell lines were tumorigenic when grafted into
C57BL/6, CEA424/Tag or CEA424/Tag-CEA-transgenic hosts and no significant differences in tumor take and tumor growth
were observed in the different hosts. Although no spontaneous tumor rejection was observed, vaccination of C57BL/6 mice
with lysates from gastric carcinoma cell lines protected C57BL/6 mice from tumor challenge, demonstrating the tumorigenicity
of the tumor cell lines in nontransgenic mice of the H-2b haplotype.
Conclusion:  These tumor cell lines grafted in different syngeneic hosts should prove to be very useful to optimize
immunotherapy regimens to be finally tested in transgenic animals developing primary gastric carcinomas.
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Background
Gastric cancer is the second most common cancer world-
wide[1]. It is often not detected until an advanced stage;
consequently, the 5-year survival rates are low (10 to
20%). Owing to local invasion and metastasis, radiation
therapy or chemotherapy does not significantly increase
the length or quality of life of patients with advanced gas-
tric cancer. Therefore, development of new neoadjuvant
and adjuvant treatment modalities are needed. Immuno-
therapy might be a promising alternative option. A
number of immunotherapy approaches like adoptive
transfer of tumor-specific T cells, and vaccination using
either undefined tumor antigens derived from tumor
lysates and tumor cell lines or defined tumor antigens
commonly presented by dendritic cells are being evalu-
ated for various cancers[2,3]. For gastric cancers, immuno-
therapy was not taken seriously into consideration due to
the concept that gastric cancer is poorly immunogenic.
Therefore, only a small number of clinical immuno-
therapy trials have been reported [4-7]. In addition, only
a limited number of tumor-associated antigens with
potential use for immunotherapy have been identified [8-
11]. Consequently, the capability of the immune system
to recognize and eradicate gastric cancers is largely
unknown. To gain insight into the efficacy of various
immunotherapies for the treatment of gastric cancer and
to elucidate the underlying mechanism of induced
immune responses animal models of gastric adenocarci-
noma are indispensable.
To this end, several groups including ours have recently
established transgenic or knock-out mouse strains which
develop gastric adenomas or adenocarcinomas in various
parts of the stomach after different latencies[12]. We have
developed a transgenic gastric carcinoma C57BL/6 mouse
model based on a SV40 large T antigen (SV40 Tag) trans-
gene controlled by a human carcinoembryonic antigen
(CEA) gene promoter (from -424 to -8 of the translational
start site)[13]. In 100% of the animals, dysplastic crypt
formation in the stomach mucosa is observed in the
pyloric region already in 30 day old CEA424/SV40 Tag-
transgenic mice. Dysplasia progresses to invasive carcino-
mas and by day 50 the whole pyloric gastric mucosa has
been replaced by carcinoma cells. Between the age of 90
to 110 days the transgenic mice become moribund and
die probably of undernourishment due to blockage of the
pylorus[13]. The control of Tag expression by a minimal
CEA gene promoter allows the tumor-directed expression
of CEA by crossing CEA424/SV40 Tag-transgenic mice
with human CEA-transgenic C57BL/6 mice, which express
the CEA transgene in a similar spatiotemporal expression
pattern as found in humans[13,14]. The human tumor
marker CEA is expressed in many human adenocarcino-
mas including more than 50% of gastric carcino-
mas[15,16]. CEA is increasingly used as target antigen for
a variety of antibody- and cell-mediated tumor immuno-
therapy approaches [17-19]. CEA and Tag are suitable
immunotherapy target antigens since a number of T cell
epitopes of these antigens have been identified in C57BL/
6 mice [20-22]. Although these transgenic mouse strains
mirror very closely gastric adenocarcinoma development
in humans, experimentation with these mice is relatively
time consuming and expensive due to the difficulties to
determine tumor growth and the requirement of breeding
transgenic mice. Therefore, it is desirable to have a syn-
geneic transplantable tumor system of gastric adenocarci-
nomas in immunocompetent mice for optimization of a
given immunotherapy protocol before it is evaluated in
the transgenic mice. Here we describe murine gastric ade-
nocarcinoma cell lines established from spontaneously
developing tumors of SV40 Tag-transgenic mice that are
tumorigenic in both syngeneic wild type and transgenic
mice.
Methods
Mouse strains and cell lines
CEA424/Tag-transgenic mice (C57BL/6-Tg(CEACAM5-
Tag)L5496Wzm), CEA-transgenic mice (C57BL/6-
Tg(CEACAM5)2682Wzm; CEA2682) and F1 mice from a
cross between CEA424/Tag-transgenic and CEA-trans-
genic mice have been described previously [13,14]. Mean-
while the transgenic lines have been backcrossed to
C57BL/6 mice (H-2b) for more than 15 generations. The
transgenic lines as well as C57BL/6 mice (Charles River,
Sulzfeld, Germany) were bred and kept under standard
pathogen-free conditions in the animal facility of the
Institute for Surgical Research, Ludwig-Maximilians-Uni-
versity of Munich. The animal experiments were per-
formed after approval by the local animal welfare
committee. For tumorigenicity and immunogenicity
assays mice were used at 8–12 weeks of age. African green
monkey kidney Cos7L cell line was obtained from the
American Tissue Culture Collection (ATCC, Rockville,
MD). The BALB/c-derived fibrosarcoma Meth-A was
kindly provided by W. Deppert (Heinrich-Pette-Institut,
Hamburg). Meth-A-CEA cells were obtained by transfec-
tion of Meth-A cells with the pRc/CMV-CEA expression
plasmids using FuGENE™ 6 transfection reagent (Roche
Molecular Biochemicals, Switzerland) according to the
manufacturer's instruction. Meth-A-cTag and RBL5/T
transfectants were previously described[23].
Establishment of gastric carcinoma cell lines
The gastric carcinomas used to establish tumor cell lines
were obtained from 8 different, 13 week-old mice. Four
derived from CEA424/Tag-transgenic mice and 4 from
CEA424/TAg-CEA-double transgenic mice. The names of
the cell lines derived from the latter mice are marked by
the superscript "CEA". All cultures were performed in
RPMI1640 supplemented with 10% heat inactivated fetalBMC Cancer 2006, 6:57 http://www.biomedcentral.com/1471-2407/6/57
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calf serum (FCS "Gold"; PAA Laboratories, Coelbe, Ger-
many), 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/
ml streptomycin, non-essential amino acids and 1 mM
sodium pyruvate (GIBCO/Invitrogen, Karlsruhe, Ger-
many), further referred to as tumor medium (TM). Tumor
tissues were extensively washed in phosphate-buffered
saline (PBS) supplemented with 200 µg/ml gentamicin
and 2.5 µg/ml amphotericin B (GIBCO/Invitrogen), cut
into 1 mm3 pieces with a scalpel and plated in tissue cul-
ture flasks containing TM. The culture medium was
changed every 3–4 days. Epithelial cells and fibroblasts
growing out of the tissue fragments were separated by cell
scraping, selective trypsinization and selective passaging
with 1,000 U/ml collagenase and 500 U/ml hyaluroni-
dase (Biochrom, Berlin, Germany). During dissociation,
the flasks were monitored under an inverted microscope
and digestion was stopped when fibroblasts but not epi-
thelial cells were detached (trypsin) or vice versa (colla-
genase/hyaluronidase). This procedure was repeated
weekly until all fibroblasts were eliminated from the
tumor cell cultures. During generation of the 424GC cell
line, a fibroblast culture was established from contami-
nating fibroblasts (424 fibroblasts). Spheroids formed
within 5–7 days after seeding 0.5 × 103 mGC8 cells into
Noble agar (Sigma-Aldrich, Taufkirchen, Germany)-
coated 96-well plates (TPP-Biochrom, Berlin, Germany)
in 200 µl TM which was replaced with fresh medium every
two days. To assess viability of cells on the surface of the
spheroids, spheroids were incubated with FITC-labeled
annexin V (Annexin V FITC Apoptosis Detection Kit; Cal-
biochem, Merck Biosciences, Darmstadt, Germany) for
detection of apoptotic cells or with propidium iodide to
identify necrotic cells according to the manufacturer's rec-
ommendations.
Flow cytometry analyses
For surface staining cells were trypsinized, washed with
PBS and suspended in PBS/0.5% w/v bovine serum albu-
min (BSA) supplemented with 0.02% w/v sodium azide.
For induction of MHC molecules, cells were incubated
with 20 ng/ml of interferon-γ (IFNγ ; Peprotec, London,
UK) for 24 hours prior harvesting. Non-specific binding
of antibodies to Fc receptors was blocked by preincuba-
tion of the cells with 1 µg/106 cells of anti-CD16/CD32
monoclonal antibody (mAb) 2.4G2 (BD Pharmingen,
Heidelberg, Germany) for 15 min. Subsequently the cells
were incubated with 0.5 µg/106 cells of the mAb of interest
for 30 min at 4°C, washed twice, and where appropriate,
subsequently reacted with a second-step antibody for 15
min at 4°C. Cells were washed twice and analyzed using
a FACScan (BD, Mountain View, CA). Dead cells were
excluded by propidium iodide staining. The following
reagents and mAbs against murine antigens from BD
Pharmingen were used: phycoerythrin (PE)-conjugated
mouse IgG2a anti-I-Ab, biotinylated mouse IgG2a anti-H-
2Db, PE-conjugated mouse IgG2aanti-H-2Kb, PE-conju-
gated anti-mouse CD80/B7-1, PE-conjugated rat IgG2a
anti-mouse CD40, PE-conjugated rat IgG2a anti-mouse
CD86/B7-2, fluorescein isothiocyanate (FITC)-conju-
gated, Armenian hamster IgG2 anti-mouse CD80/B7-1.
FITC-conjugated rat IgG1 mAb R3-34, PE-conjugated rat
IgG1  mAb R3-34, PE-conjugated mouse IgG2a  anti-rat
SIRP, FITC-conjugated Armenian hamster IgG2anti-KLH
and PE-conjugated rat IgG2amAb served as isotype con-
trols. Mouse anti-mouse CEACAM1 mAb CC1, rat anti-
mouse CEACAM1 AgB10 [24] and rat anti-mouse E-cad-
herin and anti-mouse EpCAM mAbs were a kind gift from
K. Holmes, University of Colorado, B. B. Singer, Charité
Berlin, and P. Ruf, Trion Research, Munich, respectively.
The cross-reactive mouse anti-human CEACAM mAb 4/3/
17 (specific for human CEA/CEACAM5 in the mouse)
were purchased from GENOVAC (Freiburg, Germany).
Murine antibodies were detected with PE-conjugated goat
anti-mouse IgG, rat antibodies with FITC-conjugated don-
key anti-rat-IgG (DAKO).
Detection of CEA and SV40 Tag by Western blotting
Exponentially growing gastric carcinoma cells, Cos7L
cells, Cos7L-CEA transfectants, Meth-A cells and Meth-A-
cTag transfectants which express a truncated cytoplasmi-
cally located SV40 Tag were harvested by trypsinization.
Cells were washed three times in PBS and lysed at a den-
sity of 106 cells/ml in lysis buffer. Protein concentration
was determined using the BCA Protein Assay Kit (Pierce,
Rockford, Illinois, USA). Cell extracts corresponding to 10
µg of protein were separated by electrophoresis through
10% SDS polyacrylamide gels (Invitrogen, Karlsruhe, Ger-
many), transferred to polyvinyliden fluoride membranes
and incubated with 10 µg/ml anti-human CEACAM mAb
4/3/17 or a 1:100 diluted hamster anti-SV40 Tag antise-
rum (a kind gift by K.-H. Scheidtmann, University of
Bonn). Bound antibodies were reacted with horse-radish
peroxidase-labeled secondary antibodies and visualized
using a chemiluminescence-based detection system (ECL;
Amersham Biosciences Europe GmbH, Freiburg, Ger-
many).
Cell doubling time determination
In vitro doubling times of the cell lines were determined
by plating the gastric carcinoma cells in 24-well plates in
TM at the indicated starting cell numbers and counting of
the cell samples from triplicate wells after gentle trypsini-
zation every 3 days for 21 days. The in vivo doubling times
were calculated from tumor volume measurements (see
below) after inoculation with three different starting cell
numbers (three mice per group). Doubling times were cal-
culated from the log phase of the growth curves.BMC Cancer 2006, 6:57 http://www.biomedcentral.com/1471-2407/6/57
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Morphology of gastric carcinoma cell lines grown as monolayer cultures or as three dimensional spheroids Figure 1
Morphology of gastric carcinoma cell lines grown as monolayer cultures or as three dimensional spheroids. (A) 
The cell lines show a slightly different epithelial morphology. Most cells of all cell lines contain a characteristic intracellular vac-
uole (arrows) which probably contains mucinous material stained red by the PAS method (last picture right in lower panel). (B) 
Spheroid formed by culturing mGC8 tumor cells on soft agar: left, phase contrast; right, fluorescence staining of necrotic cells 
with propidium iodide (red) and apoptotic cells with FITC-labeled annexinV (green, marked by arrowheads) as described in 
"Material and Methods". Magnification: bars correspond to 10 µm. mGC, murine gastric carcinoma.
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Tumorigenicity and immunogenicity of the cell lines
For tumorigenicity assessment tumor cells were washed
three times in PBS and 50 µl of cell suspensions with the
indicated cell numbers were injected subcutaneously into
the shaved right flank of the mice. To determine the
immunogenicity, 107 tumor cells/ml were lysed by two
consecutive freeze and thaw cycles. Mice were immunized
four times at weekly intervals with 106 lysed tumor cells
Cell surface expression of epithelial markers (A) and MHC class I and II molecules (B) Figure 2
Cell surface expression of epithelial markers (A) and MHC class I and II molecules (B). Gastric carcinoma cell lines 
were reacted either with PE-labeled (H-2Kb, H-2Db, I-Ab) or with unlabeled mAbs (CEACAM1, E-cadherin, EpCAM) followed 
by incubation with PE-labeled anti-mouse IgG or FITC-labeled anti-rat IgG and analyzed by flow cytometry. Histograms display 
the results obtained with antibodies against relevant antigens with (open gray) or without (open black) prior IFNγ stimulation 
and irrelevant antigens (gray filled curves).
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into the right flank. Three weeks later, the mice were chal-
lenged by subcutaneous injection of 3 × 106 viable tumor
cells into the left flank. Experimental groups consisted of
4–6 mice. Tumor development was followed by serial
measurements of the tumor size and the tumor volume
was calculated according to the equation: tumor volume
(mm3) = d2 × D/2, where d and D were the shortest and
the longest tumor diameter, respectively. Animals were
euthanized when the tumors reached a volume of 300
mm3.
Generation of Tag-specific cytotoxic T lymphocytes (CTL) 
and stimulation by gastric carcinoma cell lines
CTLs were generated as previously described[23]. Briefly,
mice were intradermally inoculated with 1 µm gold parti-
cles coated with a Tag expression plasmid (BMG/cT-Ag.1
[23]) into the shaved abdominal skin using a helium pres-
sure (200 psi) powered biolistic device (Helios gene gun;
Bio-Rad Laboratories GmbH, Munich, Germany). Spleen
cells obtained 14 days post vaccination were restimulated
at weekly intervals with irradiated RBL5/T transfectants in
RPMI-1640/10% FCS supplemented with 30 IU/ml IL-2.
RBL5/T is a Rauscher virus-transformed T-lymphoma cell
line derived from a C57BL6 (H-2b) mouse transfected
with a SV40 Tag expression plasmid. To generate epitope-
specific CTL, spleen cells taken 10 days post vaccination
were restimulated in vitro with irradiated, Tag peptide-
pulsed RBL5 cells. The T1, T2/3 and T4 epitope specificity
of the CTL was controlled by determination of the IFNγ
content of media upon stimulation with peptide-pulsed
target cells using ELISA.
Cytokine detection by ELISA
For capture and detection of IFNγ in supernatants by con-
ventional sandwich ELISA, we used mAb R4-6A2 and
biotinylated mAb XMG1.2, respectively (BD Pharmin-
gen). Extinction was analyzed at 405/490 nm on a TECAN
microplate ELISA reader (TECAN Crailsheim, Germany)
with the EasyWin software (TECAN). The detection limit
of the ELISA for IFNγ was 20 pg/ml.
Results
Establishment and phenotype of the gastric carcinoma cell 
lines
From 8 gastric carcinoma samples 7 cell lines could be
established. Four cell lines were derived from CEA424/
Tag-transgenic mice (424GC, from a male mouse; mGC3,
female; mGC5, male; and mGC8, female) and three lines
from CEA424/Tag-CEA-transgenic mice (mGC2CEA, male;
mGC4CEA, male; mGC11CEA, female). The time needed to
obtain pure epithelial cell cultures varied greatly (mean 6
months, range 3–16 months). Although the tumor cells
grow as adherent cells in culture, they tend to form aggre-
gates rather than spreading over the culture substrate (Fig.
1A). The epithelial origin of the tumor cells was proven by
morphological criteria including the presence of mucin
within the cells (Fig. 1A) and the expression analysis of
protein commonly expressed in epithelial cells (EpCAM,
E-cadherin, CEACAM1) (Fig. 2A). A reduced content of
mucin was found in all cell lines compared with the con-
tent in normal gastric epithelial cells but similar to that
found in tumor cells within the gastric carcinoma in trans-
genic mice (Fig. 1A and [13]). All cell lines displayed
CEACAM1 and EpCAM on their surface except
mGC11CEA, none of them expressed E-cadherin (Fig. 2A
and data not shown). All cell lines expressed MHC class I
H-2K and, and at a much lower level, H-2D molecules
(Fig. 2B). Expression of both proteins was strongly
enhanced by IFNγ stimulation. No expression of MHC
class II molecules (I-Ab) was detected (Fig. 2B and data
not shown). CD54, CD80, CD86 or CD95 were not
detected on any cell line (data not shown).
In order to determine the potential of the cell lines to be
used for the generation of three-dimensional tumor mod-
els we analyzed tumor cell spheroid formation in vitro. As
illustrated in Fig. 1B the cell lines formed compact tumor
cell spheroids after 8 days of culture when 103 cells were
seeded into soft agar-coated 96-well plates. Only minor
intra-experimental variation was observed concerning the
size of the spheroids. Staining with propidium iodide and
FITC-labeled annexin V demonstrated that at least the sur-
face layer of the spheroids consisted of viable cells with
very few dead cells attached to it (Fig. 1B).
Transgene expression by the gastric carcinoma cell lines
CEA and Tag can serve as tumor-specific antigens (TSA) or
tumor-associated antigens (TAA) after transplantation of
the newly established tumor cell lines in immunocompe-
tent syngeneic C57BL/6 and CEA- or Tag-transgenic mice,
respectively. Although instrumental in tumor formation,
Tag transgene expression is not always found in tumor cell
lines derived from Tag-transgenic mice, like in TRAMP
tumor cell lines[25]. This prompted us to analyze the
expression and MHC class I-restricted presentation of the
Tag transgene as well as the expression of CEA in the
established gastric carcinoma cell lines. CEA cell surface
expression was analyzed in cell lines derived from gastric
tumors from double transgenic mice by flow cytometry
and Western blot analysis. While the expression of the
CEA transgene is regulated by the complete promoter
region of the human CEA gene the expression of the Tag
is controlled by a minimal -424/-8 bp CEA promoter (Fig.
3A). All three double-transgenic cell lines expressed CEA
on the cell surface (Fig. 3B). In the gastric carcinoma cell
line mGC2CEA  transgene-expressed CEA exhibited a
molecular weight of 180 kDa similar to the one found in
SV40-transformed African green monkey kidney cells sta-
bly transfected with a CEA expression vector and to CEA
found in humans. As expected, no CEA was detected inBMC Cancer 2006, 6:57 http://www.biomedcentral.com/1471-2407/6/57
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Expression of CEA and Tag by gastric carcinoma cell lines derived from CEA424/Tag- or CEA424/Tag × CEA-transgenic mice Figure 3
Expression of CEA and Tag by gastric carcinoma cell lines derived from CEA424/Tag- or CEA424/Tag × CEA-
transgenic mice. (A) Structure of the CEA and CEA424/Tag transgenes. The exons 1–10 of the human CEA gene contained 
within the insert of cosmid clone cosCEA1[14] are shown as color coded boxes (light blue, leader; red, IgV-like domain; blue 
IgC-like domain; gray, transmembrane domain; white, 5' and 3'-untranslated region exons. Flanking vector sequences are indi-
cated as black boxes. The location of the CEA minimal promoter present in the SV40 Tag gene transgene is indicated by dotted 
lines, the names of the transgenic lines are shown in the left margin. (B) Flow cytometry was performed by labeling of the indi-
cated cells either with the CEA-specific mAb 26/3/13 (filled curves) or an isotype-matched antibody (open curves) followed by 
PE-labeled goat anti-mouse IgG antibodies. (C, D) For Western analysis, 10 µg of total protein from extracts of 424GC or 
mGC8 cells established from CEA424/Tag-transgenic mice and mGC2CEA and mGC4CEA cells from CEA424/Tag × CEA-trans-
genic mice were size separated by SDS polyacrylamide gel electrophoresis, transferred to a membrane and reacted with the 
CEA-specific mAb 26/3/13 (C) or hamster polyclonal anti-Tag antibodies (D). Extracts from Cos7L-CEA and Meth-A cells sta-
bly transfected with expression vectors encoding CEA or a Tag lacking a region with the nuclear localization signal (cTag) 
served as a positive control. The sizes of protein markers are indicated in the left margins.
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424GC cells, which were established from a CEA-negative
Tag-transgenic mouse (Fig. 3C). Tag was found to be
expressed by Western blotting and immunofluorescence
analysis in all cell lines derived from single and double-
transgenic mice (Fig. 3D and data not shown). This find-
ing also supports the origin of the cell lines from the stom-
ach carcinomas. Furthermore, the 424GC cell line
efficiently presented endogenously processed Tag-derived
MHC class I-restricted presentation of Tag epitopes by murine gastric carcinoma cell lines Figure 4
MHC class I-restricted presentation of Tag epitopes by murine gastric carcinoma cell lines. (A) Epitope-specific 
CTL generated in C57BL/6 mice by DNA immunization with a Tag expression vector and subsequent expansion by in vitro 
stimulation with Tag peptide-loaded RBL5 cells were incubated with irradiated 424GC, 424 fibroblasts, RBL5 and Tag T1, T2/3 
or T4 peptide-pulsed RBL5 cells for 24 h and their IFNγ secretion into the culture media was determined by ELISA. Secretion 
of IFNγ by CTL stimulated with 424GC cells indicates that these cells present SV40Tag-specific peptides in an MHCI-restricted 
manner. (B) Coculture of 424GC and 424 fibroblasts were treated with 107 Tag-specific CTL in a petri dish for 48 h. Thereaf-
ter, non-adherent (dead) cells were removed. Left, coculture before CTL treatment; right, coculture after treatment. Arrows 
indicate the position of the tumor cells before addition of CTL.
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In vivo (A) and in vitro growth characteristics (B) of murine gastric carcinoma cell lines Figure 5
In vivo (A) and in vitro growth characteristics (B) of murine gastric carcinoma cell lines. Three mice each were 
injected with the indicated tumor cell doses. Tumor growth was quantified by two perpendicular measurements of the tumor 
diameter and calculation of the volume as described in the Materials and Methods section. To determine in vitro growth char-
acteristics, cells were grown in 24-well plates starting with the indicated cell numbers. At different time points cells from tripli-
cate wells were harvested and counted. Results are shown as mean +/- standard deviation (SD). Best fit curves as well as 
doubling times in days (shown in brackets) were calculated using the GraphPad software.
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peptides, especially the T1 epitope, in a MHC-I restricted
manner as determined by the induction of IFNγ secretion
byTag-specific CTL (Fig. 4A). Furthermore, the cell lines
were efficiently killed by Tag-specific CTL in cytotoxic
assays (Fig. 4B).
Tumorigenicity of the gastric carcinoma cell lines
To determine the tumorigenicity of the cell lines, various
numbers (1 × 105; 3 × 105; 1 × 106) of cells were injected
subcutaneously into C57BL/6 mice. All cell lines were
able to form tumors in 100% of the animals, if at least 3 ×
105 tumor cells were injected (Fig. 5A). The tumors grew
nearly exponentially without any delay until they reached
a volume of 300 mm3. No distant metastases could be
detected during the observation time. Western blot analy-
Growth of gastric carcinoma cell lines in wild-type and trans- genic mice Figure 6
Growth of gastric carcinoma cell lines in wild-type 
and transgenic mice. 3 × 105 424GC cells were injected 
subcutaneously into C57BL/6 and CEA424/Tag-transgenic 
mice (A) or 3 × 105 mGC11CEA cells were injected into 
C57BL/6 and CEA424/Tag × CEA-double transgenic mice 
(B). Tumor growth was quantified by two perpendicular 
measurements of the tumor diameter and calculation of the 
volume as described in the Materials and Methods section. 
Results are shown as mean +/- SD (n = 3).
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Immunogenicity of mGC cells. (A) Anti-CEA antibodies 
were determined in the serum of C57BL/6 and CEA-trans-
genic mice using flow cytometry. All mice had progressively 
growing tumors without overt necrosis after transplantation 
and growth of the indicated cell lines for 35–40 days. 
mGC4CEA cells were incubated with the serum of the indi-
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(B, C) Three C57BL/6 mice each were injected subcutane-
ously three times at weekly intervals with 1 × 106 mGC8 
cells killed by two freeze-thaw cycles. Two weeks after the 
last vaccination, the mice were challenged by injection with 1 
× 106 (B) and 3 × 106 (C) live mGC8 cells, respectively 
(filled-in circles). As a control, tumor cells were injected in 
non-immunized mice (open circles). Tumor volumes were 
calculated as described in Material and Methods section. 
Results are shown as mean values +/- SD.
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sis performed on transplanted tumors demonstrated that
both transgenes were expressed by the cell lines in vivo
(data not shown). The doubling times of the tumor cells
in vivo at a starting tumor load of 106 cells varied between
7.2 (mGC8) and 13.8 days (mGC3) (Fig. 5A). In vitro, all
cell lines exhibited similar doubling times of about 3 days
(Fig. 5B). We further compared subcutaneous tumor for-
mation of the cell lines in wild-type (C57BL/6) and trans-
genic mice. No significant differences were observed in
tumor take and tumor growth for the cell line 424GC
when injected subcutaneously into wild-type or CEA424/
Tag-transgenic mice (Fig. 6A) and for mGC11CEA cells after
injection into wild-type and CEA424/Tag-CEA-transgenic
mice (Fig. 6B).
Immunogenicity of the gastric carcinoma cell lines
The similar growth of the tumor cell lines in wild-type and
transgenic mice indicates that no significant immune
response to either tumor antigen (Tag, CEA) occurred in
tumor bearing mice. Indeed, no Tag-specific CTL could be
identified in the spleen of tumor bearing wild-type mice
upon progressive subcutaneous growth of Tag-expressing
gastric carcinoma cells (data not shown). However, when
double transgenic cell lines grew in mice, CEA-specific
antibodies could be identified in wild-type C57BL/6 mice
but not in CEA-transgenic mice (Fig. 7A). Furthermore,
three immunizations of C57BL/6 mice with 106 freeze-
thawed mGC8 tumor cells at weekly intervals either pre-
vented growth of subcutaneously injected live mGC8 cells
completely or tumor outgrowth was delayed for nearly
three weeks depending on the injected tumor cell dose
(Fig. 7B, C). These experiments demonstrate that the
tumor cell lines are immunogenic under certain condi-
tions. However, C57BL/6 mice do not spontaneously
mount an efficient tumor progression-limiting immune
response to either tumor antigen during subcutaneous
tumor growth.
Discussion
The main goal of the present study was to establish a ther-
apeutic model of gastric cancer in immunocompetent
mice that would provide an animal model to evaluate
anti-tumor immunity and immunotherapeutic strategies.
Towards this end, the murine cell lines described in this
paper were established from spontaneously developing
gastric tumors of two different transgenic mouse strains.
Together with the transgenic mice, these cell lines now
provide a useful experimental system for gastric cancer. A
similar experimental system for prostate cancer, the
TRAMP mice in combination with the C1 and C2 cell lines
has already proven its great impact on prostate cancer
research [25-27]. This is of particular importance, since in
contrast to the large number of human gastric carcinoma
cell lines to our knowledge only one murine gastric carci-
noma cell line is available. This cell line was established
from the forestomach but not from the glandular part of
the stomach from which the most common carcinomas
arise in humans[28].
The cell lines which we have established from CEA424/
Tag-transgenic and CEA424/Tag-CEA-transgenic mice,
have most likely originated from transformed gastric glan-
dular epithelial cells for several reasons: all cell lines have
an epithelial phenotype, contain reduced but detectable
amounts of mucin, and express, with one exception
(mGC11CEA), the epithelial cell marker EpCAM. The
mGC11CEA  cell line which was established from a
CEA424/Tag-CEA-double transgenic mouse which
expresses CEA, a molecule that is exclusively expressed by
epithelial cells. Finally, all cell lines are tumorigenic and
form tumors readily when transplanted subcutaneously
into syngeneic mice (Fig. 5).
The murine gastric carcinoma cell lines as well as the pri-
mary gastric carcinomas mimic closely human gastric car-
cinomas and derived cell lines in expressing CEA (when
established from tumor-bearing CEA-transgenic
mice)[29], upregulate CEACAM1[30], downregulate E-
cadherin expression[31] and express EpCAM[32]. CEA
has been found to increase tumorigenicity by blocking
differentiation[33], inhibiting anoikis, a mechanism
which results in destruction of epithelial cells once
detached from their basement membrane[34] and dis-
rupting cell polarity[35]. CEACAM1 is downregulated in
colonic, prostate and mammary carcinomas and its re-
expression reduces the tumorigenicity of epithelial tumor
cell lines[36,37]. Therefore, CEACAM1 is considered a
tumor suppressor. On the other hand, CEACAM1 expres-
sion appears to be upregulated in subsets of other tumors
like in stomach carcinomas in humans and mice[29,30].
It was shown for melanoma and lung adenocarcinomas,
that CEACAM1 upregulation is significantly associated
with a poor prognosis[30,38-40]. Furthermore, EpCAM
has a direct effect on tumor cell proliferation by upregula-
tion of c-myc and cyclin A/E[32] and loss of E-cadherin
expression is observed in undifferentiated-type gastric car-
cinomas upon mucosal spread and deep invasion beyond
the submucosa[31]. Taken together, these findings imply
that similar molecular mechanisms are responsible for the
tumorigenic properties of the murine gastric carcinoma
cell lines as found for human gastric carcinomas and
derived cell lines.
Although spontaneously developing and autoch-
thonously growing tumors are clinically the most relevant
tumor models, in many cases transplantable tumors are
needed to create a large body of data from multiple treat-
ment regimens. From an economic point of view it is rea-
sonable to test only the most promising strategies in the
more challenging transgenic mouse models. In this con-BMC Cancer 2006, 6:57 http://www.biomedcentral.com/1471-2407/6/57
Page 12 of 15
(page number not for citation purposes)
text it is advantageous that the Tag and CEA-expressing
gastric carcinoma cell lines are growing equally well in
transgenic and wild-type C57BL/6 mice despite their dif-
ferent immunogenicity in both hosts. This permits the
stepwise optimization of therapy strategies in models
gradually approaching the patients' situation with respect
to tumor antigen tolerance. Therefore, in wild-type mice
Tag and CEA can serve as TSA, which could be used as tar-
get antigens in different immunotherapy approaches. In
this particular setting, many immunotherapies should be
effective to a certain extent, which is a prerequisite for the
optimization of the therapy protocol. Indeed, we could
demonstrate in the present report that simple immuniza-
tion with tumor cell lysates is able to induce protective
anti-tumor immunity (Fig. 7). Once the therapy protocol
has been optimized for the wild-type model, the intricacy
of the model can be increased, e.g. by transplanting the
tumor cells into transgenic mice. In mice expressing only
one of the two potential tumor antigens, the antigens
would either function as TSA or TAA, whereas in CEA424/
Tag-CEA double-transgenic mice both antigens would
represent TAA (Fig. 8). In these different models, further
rounds of therapy optimization can be performed. This is
expected to lead to an optimal immunotherapy protocol
effective in transgenic mice suffering from spontaneously
developing and autochthonously growing tumors which
represent the most relevant model for human cancer. In
this context, the consistent expression of the widely used
and well-characterized tumor antigens Tag and CEA as
well as high level (inducible) expression of MHC class I
molecules needed for antigen presentation to cytotoxic T
cells are instrumental for the use of the cell lines to study
antigen-specific tumor immune therapies. Indeed, we
could demonstrate that the level of Tag expression of the
424GC cell line is sufficient to be killed by syngeneic Tag-
specific CTL. In contrast, other Tag-based transgenic
Possible combinations of gastric tumor cell lines and mouse strains to generate mouse models which differ in the quality of the  expressed tumor antigens and the anatomical location of the tumors Figure 8
Possible combinations of gastric tumor cell lines and mouse strains to generate mouse models which differ in 
the quality of the expressed tumor antigens and the anatomical location of the tumors. The quality of the poten-
tial tumor antigens Tag and CEA can be manipulated by ectopic transplantation of Tag and/or CEA-positive tumor cell lines in 
wild-type C57BL/6 mice, Tag- or Tag × CEA-transgenic mice. Depending on whether the proteins represent self or foreign 
antigens they can be regarded as TAA or TSA. In spontaneously developing autochthonous tumors both CEA and Tag repre-
sent TAA.
C57BL/6 CEA424/Tag
transplantable
C57BL/6
Established cell lines
(CEA424/Tag-CEA)
mGC11CEA
mGC2CEA
mGC4CEA
CEA424/Tag-transgenic 
mice (H-2b)
spontaneous
gastric carcinoma
CEA424/Tag-CEA-transgenic
mice (H-2b)
Established cell lines
(CEA424/Tag)
424GC
mGC3
mGC5
mGC8
transplantable
CEA424/Tag CEA CEA424/Tag-CEA
TSA
TSA
TAA
TSA TAA TAA  CEA
Tag TSA TAA TSA TAABMC Cancer 2006, 6:57 http://www.biomedcentral.com/1471-2407/6/57
Page 13 of 15
(page number not for citation purposes)
mouse models where primary tumor-derived cell lines
exist, like the TRAMP model (cell lines C1, C2 and C3),
have been reported to lack Tag expression in derived cell
lines[25].
It is of particular relevance that the gastric cancer cell lines
express different potential target antigens since the type of
immunological tolerance may differ between different
tumor antigens and between different transgenic strains.
Indeed it was shown that depending on the expression
pattern of Tag in different Tag-transgenic mice one can
encounter all facets of immunological tolerance, ranging
from immunological ignorance to central toler-
ance[25,41-43]. There is strong evidence that also in
CEA424/Tag mice central tolerance against the Tag exists
(R. K., and W. Z., unpublished results). On the other
hand, only a peripheral tolerance appears to exist for CEA
in CEA2682-mice [44-47]. If needed, this allows testing of
strategies to break tolerance to CEA without interference
of the viral antigen Tag.
Finally, the cell lines generated from the transgenic mice
have significant advantages to other subcutaneously trans-
plantable CEA-expressing murine tumor cell lines, since
in the transgenic cell lines CEA is expressed under the con-
trol of its naturally existing regulatory elements, which
may be relevant in respect to possible immune escape
mechanisms (i.e. escape variants).
Conclusion
For the optimization of tumor immunotherapy protocols,
a series of in vivo models are needed which gradually make
higher demands on the efficacy of the therapy. Ideally the
whole series should be composed of the same cellular sys-
tem and reach high relevance for the human disease for
which immunotherapy is to be developed. The model sys-
tem composed of wild-type C57BL/6, CEA424/Tag,
CEA2682 and CEA424/Tag-CEA transgenic mice and the
respective tumor cell lines described in the present report
offers such a model for immunotherapies of gastric carci-
noma. The established murine gastric adenocarcinoma
cell lines may also be helpful for the identification of new
tumor antigens relevant to gastric cancer as well as for the
understanding of molecular events during gastric cancer
progression.
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